Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 5/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945372 | 0.88 | SMN1; SMN2 (0.52) | MAOAMAOBCHRM4HTR1D | |
| SCHEMBL8095794 | 0.87 | HRH3 (0.58) | HRH3MAOAMAOBHTR1D | |
| SCHEMBL5532964 | 0.87 | HRH3 (0.58) | HRH3MAOAMAOBPRKAA2AKT1 | |
| SCHEMBL4242392 | 0.83 | CHRM4 (0.49) | HRH3CHRM4HTR1D | |
| SCHEMBL5529129 | 0.82 | HTR1D (0.52) | HTR1D | |
| SCHEMBL8095863 | 0.81 | HTR1D (0.52) | MAOAMAOBHTR1D | |
| SCHEMBL8094309 | 0.81 | HTR1D (0.43) | CHRM4AKT1HTR1D | |
| SCHEMBL8096407 | 0.79 | CHRM4 (0.40) | HRH3MAOAMAOBCHRM4GPR6 | |
| SCHEMBL8087949 | 0.79 | SCN1A (0.45) | HTR1D | |
| SCHEMBL8100848 | 0.79 | HRH3 (0.44) | HRH3MAOAMAOBCHRM4GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | HRH3 1043/4885MAOA 2091/4885MAOB 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.